MTOR and lymphangioleiomyomatosis: Due to the association of LAM and endometrial cancer with the mTOR activation pathway, patients with LAM should be monitored closely and any suspicious gynecological lesion should be investigated further to rule out malignancy. Studies should be conducted to investigate the effectiveness of sirolimus in the treatment of uterine malignancies to treat coexisting conditions with a common drug.